Breast Biopsy Market Segmentation:
End Users Segment Analysis
The hospital segment in the breast biopsy market is estimated to hold around 40% revenue share by 2034. The growth of this segment can be attributed to large number of patients requiring breast biopsies and hospitalization for surgery or treatment. Hospitals are also experiencing remarkable growth in numbers. For example, in 2022, there are about 6,100 hospitals in the United States.
Product Segment Analysis
The biopsy needle segment is set to hold 30% share of the global breast biopsy market by the end of 2034, impelled by increasing demand for breast biopsy procedures, including the use of biopsy needles. The growing awareness of the importance of breast biopsy procedures, including the use of biopsy needles.
Our in-depth analysis of the global market includes the following segments:
|
Product |
|
|
End User |
|
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of breast biopsy is assessed at USD 2.24 billion.
Breast Biopsy Market size was valued at USD 2.13 billion in 2024 and is expected to reach USD 3.92 billion by 2034, expanding at around 6.3% CAGR during the forecast period i.e., between 2025-2034.
Asia Pacific is anticipated to hold largest industry share of 35% by 2034.
The key market players include Hologic, Inc., Danaher CorporationBD (Becton, Dickinson, and Company)Cook Medical LLCArgon Medical Devices, Inc.B. Braun Melsungen AGC.R. Bard, Inc.Devicor Medical Products, Inc.Cardinal Health, Inc.
